Agios Reports Business Highlights and Second Quarter 2023 Financial Results Read more about Agios Reports Business Highlights and Second Quarter 2023 Financial Results
Agios Announces Exclusive Worldwide License Agreement with Alnylam for Novel siRNA for the Potential Treatment of Polycythemia Vera Read more about Agios Announces Exclusive Worldwide License Agreement with Alnylam for Novel siRNA for the Potential Treatment of Polycythemia Vera
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023 Read more about Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response Read more about Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
Jeffrey Capello Chair of the Audit Committee Jeffrey Capello Director Financial Expert Independent Director
Catherine Owen Member of the Compensation & People Committee Catherine Owen Director Independent Director
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023 Read more about Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
Agios Appoints Catherine Owen to Board of Directors Read more about Agios Appoints Catherine Owen to Board of Directors
Cynthia Smith Chair of the Compensation & People Committee Cynthia Smith Director Independent Director